Plasma Clinical Trials in Atlanta, Georgia
9 recruitingAtlanta, Georgia
Showing 1–9 of 9 trials
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Smoldering Plasma Cell Myeloma
Emory University68 enrolled1 locationNCT04776395
Recruiting
Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
ECOG-ACRIN Cancer Research Group288 enrolled707 locationsNCT03937635
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled28 locationsNCT04643002
Recruiting
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Plasma Cell Myeloma
Emory University34 enrolled1 locationNCT05208307
Recruiting
Not Applicable
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Bone PainMetastatic Malignant Neoplasm in the BonePlasma Cell Myeloma
University of Southern California100 enrolled9 locationsNCT03858205
Recruiting
Phase 1
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NeoplasmsMultiple MyelomaCardiovascular Diseases+11 more
OriCell Therapeutics Co., Ltd.81 enrolled1 locationNCT06271252
Recruiting
Phase 1Phase 2
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Multiple MyelomaPlasma Cell Disorder
Heidelberg Pharma AG78 enrolled16 locationsNCT04879043